Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study

Connor Willis; Hillevi Bauer; Trang H. Au; Jyothi Menon; Sudhir Unni; Dao Tran; Zachary Rivers; Wallace Akerley; Matthew B. Schabath; Firas Badin; Ashley Sekhon; Malini Patel; Bing Xia; Beth Gustafson; John L. Villano; John-Michael Thomas; Solomon J. Lubinga; Michael A. Cantrell; Diana Brixner; David Stenehjem

doi:10.18632/oncotarget.28318

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Addendum:

Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study

PDF | How to cite

Oncotarget. 2022; 13:1306-1306. https://doi.org/10.18632/oncotarget.28318

Metrics: PDF 700 views | ?

Connor Willis¹, Hillevi Bauer¹, Trang H. Au¹, Jyothi Menon¹, Sudhir Unni¹, Dao Tran², Zachary Rivers², Wallace Akerley³, Matthew B. Schabath⁴, Firas Badin⁵, Ashley Sekhon⁶, Malini Patel⁷, Bing Xia⁸, Beth Gustafson⁹, John L. Villano¹⁰, John-Michael Thomas¹¹, Solomon J. Lubinga¹², Michael A. Cantrell¹³, Diana Brixner¹ and David Stenehjem^1,2

¹Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
²Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, MN, USA
³Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA
⁴Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
⁵Department of Hematology and Oncology, Baptist Health Medical Group, Lexington, KY, USA
⁶Department of Radiation Oncology, MetroHealth Medical Center, Cleveland, OH, USA
⁷Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
⁸Department of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
⁹Precision Oncology Program, Saint Luke’s Cancer Institute, Kansas City, MO, USA
¹⁰Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, USA
¹¹US Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA
¹²Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA
¹³Global Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA

Published: December 06, 2022

Copyright: © 2022 Willis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: This study proceeded with institutional IRB approvals at each participating cancer center. Due to the retrospective nature of this project, a waiver of informed consent was approved by each of the listed local IRBs.

Original article: Oncotarget. 2022; 13:257–270. DOI: https://doi.org/10.18632/oncotarget.28178

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28318

Publication Alerts

Post-Publication Promotion

Addendum:

Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study